Platelet-mediated lymphocyte delivery to high endothelial venules

Circulating lymphocytes gain access to lymph nodes owing to their ability to initiate rolling along specialized high endothelial venules (HEVs). One mechanism of rolling involves L-selectin binding to peripheral node addressin (PNAd) on HEVs. Activated platelets are shown to bind to circulating lymphocytes and to mediate rolling in HEVs, in vivo, through another molecule, P-selectin, which also interacts with PNAD. In vitro, activated platelets enhanced tethering of lymphocytes to PNAd and sustained lymphocyte rolling, even in the absence of functional L-selectin. Thus, a platelet pathway operating through P-selectin provides a second mechanism for lymphocyte delivery to HEVs.

Lymphocytes continuously migrate from the blood to peripheral lymph nodes (PLNs) and other lymphoid organs. This "homing" event is mediated by sequential engagement of tissue-specific adhegion and activation pathways (1). Homing to PLNs, for instance, is dependent on the lymphocyte homing receptor L-selectin (2), which interacts with a ligand on HEVs that is defined by the monoclonal antibody mab MECA-79 (3) in mouse and human. Both MECA-79 and recombinant L-selectin immunoglobulin chimeric protein precipitate sulfated and sialylated glycoproteins that are collectively known as the peripheral node addressin (PNAD) (4, 5). Affinity-purified PNAD glycoproteins mediate L-selectin-dependent lymphocyte rolling in vitro (6, 7). Except for its physiologic expression in HEVS of PLNs, venular PNAd expression is also induced in several chronic inflammatory disease states (8). Some of these pathologic conditions, such as inflammatory bowel disease, are also associated with an increase in activated platelets both in the circulation and at vascular sites of inflammation (9). Because activated platelets interact with both leukocytes and endothelial cells in vitro, we examined whether activated platelets in the bloodstream can alter lymphocyte behavior in HEVs.

We used an in vivo model to study lymphocytes in murine PLN HEVs by intravital microscopy (10). A mAb to L-selectin, Mel-14 (2), inhibited rolling of fluorescently labeled white blood cells (WBCs) by 80 to 90% [Fig. 1 and (11)], confirming the important role of this molecule in lymphocyte homing. A subsequent injection of resting human platelets (12) into the arterial bloodstream did not detectably alter WBC behavior in HEVS (13). In contrast, platelet activation before injection resulted in a marked reappearance of endogenous rolling WBCs despite the continued presence of mab to L-selectin. These findings indicate a previously uncharacterized platelet-mediated mechanism for WBC adhesion to HEVs. Because the phenomenon was apparently L-selectin-independent, our observations further suggest that activated platelets may alter the composition of lymphocyte populations that are recruited to PLNs and other sites containing HEVS.

To define the molecular basis for platelet-dependent WBC rolling, we initially investigated the role of P-selectin (14). This molecule is expressed on the surface of activated, but not resting, platelets and endothelial cells and supports leukocyte rolling and accumulation in acutely inflamed nonlymphoid sites (15). It also mediates leukocyte interactions with activated platelets that are in circulation or bound to thrombogenic surfaces (16). When activated platelets were first incubated with mab WAPS 12.2 directed against human, but not murine, P-selectin (12), injection of treated cells did not induce WBC rolling in anti-L-selectin-treated mice. Thus, P-selectin expressed on platelets, but not on the animals' endothelial cells, was responsible for WBC rolling.

To identify the target cells and ligands for platelet P-selectin, we labeled human platelets fluorescently to directly observe their intravascular behavior. Resting platelets rarely bound to HEVs or other cells in the bloodstream (13). Activated platelets, in contrast, frequently interacted with both WBCs and the venular lining. Numerous rolling WBCs were detected with one or more brightly fluorescent platelets attached to their surface. Treatment of animals with mab Mel-14 blocked rolling of WBCs free of surfacebound platelets. In contrast, the rosettes of WBCs and
platelets persisted to roll in a cartwheeling fashion, suggesting an indirect mode of WBC adhesion to HEVs through bridging platelets. This mechanism is supported by the finding that a large number of activated platelets could bind directly to endothelial cells without WBC association. These interactions were characterized by slow rolling, occasionally followed by stationary adhesion (Fig. 2, A, C, and D), and were nearly abolished by mab WAPS 12.2 (inhibition of 80 [+ or -] 9%, mean [+ or -] SD), indicating that platelet P-selectin was responsible. In contrast, endothelial P-selectin, implicated in platelet rolling in other vascular beds (17), was not required; activated human platelets rolled in HEVs of P-selectin-deficient mice (13). Furthermore, platelet rolling mediated by platelet P-selectin in HEVs was associated with the formation of stronger or a larger number of bonds (or both) than platelet rolling on endothelial P-selectin because the mean rolling velocities measured for the former were reduced by 80% compared with those reported for the latter (17). To show that platelet rolling in HEVs was not the result of P-selectin interactions with ligands on endothelium-bound leukocytes such as P-selectin glycoprotein ligand 1 [PSGL-1; (18, 19)], we first treated some animals for 30 min with mAb Mel-14 to block leukocyte binding to HEVs. P-selectin-dependent platelet interactions persisted in the presence of anti-L-selectin and were equivalent to those seen in untreated animals (rolling fraction of 73 [+ or -] 8% versus 74 [+ or -] 18%, respectively; mean [+ or -] SD). Treatment of mice with mAb MECA-79, which reduces L-selectin-dependent homing of lymphocytes (3), also reduced adhesion of activated platelets by ~70%, suggesting that L- and P-selectin can share the same endothelial ligand, or ligands, on HEVs.

Because platelets express other adhesion molecules, we examined whether expression of cellular P-selectin alone was sufficient to promote rolling in HEVs. L1-2 lymphoma cells transfected with human P-selectin ([L1-2.sup.P-selectin]; (20)), but not vector control transfecants ([L1-2.sup.vector]), displayed slow rolling interactions in the identical segments of the lymph node (LN) microvasculature as platelets (Fig. 2B). As shown for activated platelets, mAb MECA-79 also reduced adhesion of [L1-2.sup.P-selectin] (inhibition of 59 [+ or -] 5%, mean [+ or -] SD), suggesting that P-selectin: PNAd interactions per se are sufficient for tethering and rolling in vivo.

To show directly that human PNAd contains a P-selectin ligand, we evaluated platelet and [L1-2.sup.P-selectin] binding to affinity-purified PNAd from human tonsils in vitro. Both activated platelets and [L1-2.sup.P-selectin] tethered to PNAd at a wall shear stress of [1.6 dyne.cm.sup.-2] (Fig. 3A). Once attached, >90% of the tethered platelets rolled continuously. Sticking without displacement (>30 s) or skipping rolling motions (repeated detachment and reattachment) occurred rarely (5.6 and 4.1%, respectively). Spontaneous detachment of rolling platelets was not observed. Interactions required [Ca.sup.2+] and were completely inhibited by first treating platelets or L1-2 cells with antibody to P-selectin (mAb WAPS 12.2), but not with isotype-matched control antibody to CD31 (mAb PECAM 1.3) (anti-CD31). As observed in vivo, incubation of PNAd with mAb MECA-79 also reduced P-selectinmediated rolling (Fig. 3B). This antibody recognizes sialomucin-like glycoproteins that are decorated with its carbohydrate epitope. Members of the sialomucin family mediate L-selectin-dependent tethering of peripheral blood lymphocytes to purified PNAd (21, 22) and are required for leukocyte adhesion to P-selectin (18, 19). Consistent with these earlier findings, sialylated, O-glycosylated structures were also essential for P-selectin: PNAd interactions; O-glycoprotease or neuraminidase treatment of PNAd abrogated activated platelet attachment in flow.

To date, PSGL-1, a sialomucin expressed on leukocytes (18, 19), is the only known human P-selectin ligand. It is unclear whether PSGL-1 is also expressed on endothelium and, in particular, whether PSGL-1 is a component of PNAd, which consists of several glycoproteins (65 to 200 kD). To show that a glycoprotein component of PNAd distinct from PSGL-1 can support P-selectin-mediated adhesion, we examined CD34, a major constituent of murine and human PNAd (21, 22). Purified CD34 from human tonsil PNAd supported P-selectin-mediated tethering and rolling as observed for the entire mixture of PNAd glycoproteins (Fig. 3C). However, CD34 is not a prerequisite scaffold for carbohydrate presentation to P-selectin, because its depletion from PNAd (21) resulted in only a 20% decrease in tethering of platelets compared with nondepleted material under identical biophysical conditions. This result suggests that other constituents of PNAd also present P-selectin ligand (or ligands), consistent with the concept of parallel contribution of multiple PNAd components to L-selectin binding (4, 5).
These experiments support an important role for P-selectin in adhesive interactions of activated platelets with HEVs. They also suggest a mechanism for platelet-dependent lymphocyte recruitment to HEVs in which activated platelets bound to PNAd can capture circulating lymphocytes through high-density expression of P-selectin. As many as 60% of peripheral blood T lymphocytes bear functional ligands for P-selectin (23). Thus, it is likely that platelet P-selectin and endothelial PNAd act in synergy in supporting lymphocyte recruitment to HEVs through simultaneous interactions with PSGL-1 and L-selectin, respectively. In vitro evidence supports this hypothesis: low-density binding of activated platelets to purified PNAd resulted in a threefold increase in the rolling flux of lymphocytes as compared with lymphocyte binding in the absence of platelets (Fig. 4). Furthermore, incubation of lymphocytes with mAb Dreg 200 to L-selectin (20 μg/ml) (24) abolished cell attachment to PNAd in the absence of platelets. In contrast, in the presence of surface bound platelets, mAb Dreg 200 attenuated lymphocyte attachment only to the level found with lymphocytes with functional L-selectin. These experiments also demonstrate that rolling was exclusively mediated by platelets attached to the lymphocyte surface; antibodies to either platelet P-selectin or lymphocyte PSGL-1 (19) completely blocked lymphocyte rolling.

P-selectin on platelet monolayers that cover thrombogenic surfaces can recruit circulating leukocytes in vitro and in vivo (16). However, firmly adherent platelet monolayers are rarely observed on intact endothelial cells, even in chronic inflammation. Our findings suggest a more dynamic interplay between activated platelets and vascular endothelium, characterized by reversible, but continuous, interactions with much smaller amounts of platelet deposition. Such interactions may not be apparent in histologic studies of chronic inflammation. The observation that P- and L-selectin share PNAd as a common endothelial ligand suggests a unifying mechanism for platelet and lymphocyte recruitment to lymphoid organs and inflamed tissues where PNAd is expressed. Although it is not surprising that carbohydrate moieties such as PNAd can bind to more than one selectin (25), this pathway may allow activated platelets to support a constant influx of WBCs into chronically inflamed lesions. This may provide an important synergistic mechanism to enhance the recruitment of patho-physiologically relevant lymphocyte subsets such as memory cells that express little or no L-selectin.

Delivery of WBCs by way of activated platelets may not be limited to venules that express PNAd. P-selectin-mediated platelet adhesion to endothelium may also occur in acutely inflamed nonlymphoid vascular beds where immunologically distinct L-selectin ligands have been observed (26). Moreover, recent in vivo studies have shown that exposure to atherogenic stimuli such as oxidized low density lipoprotein or cigarette smoke induces rapid P-selectin-dependent aggregation and accumulation of leucocytes and platelets in arterioles and arterres (27). In light of our present results, it is reasonable to speculate that activated platelets may have the capacity to deliver leucocytes to vascular beds such as arteries that may not express selecting or selectin ligands but do have receptors for other platelet adhesion molecules (28).

REFERENCES AND NOTES


(10.) Mice were anesthetized by intraperitoneal injection (0.2 ml) of a mixture of ketamine (5 mg/ml) and xylazine (1 mg/ml), and catheters were inserted into the right jugular vein (for injection of anesthesia and mAb), the left carotid artery (for blood pressure monitoring), and the right femoral artery (for retrograde injection of fluorescently labeled cells). Subsequently, the left subiliac LN was microsurgically prepared for intravital microscopy as described (U. H. von Andrian, Microcirculation, in press). The preparation was transferred to a custom-built intravital microscope (IV-500; Micron Instruments, San Diego, CA). For microscopic observation of endogenous microvascular WBC behavior, a bolus injection of sterile Ringer's lactate (10 ml per kilogram of body weight) containing the fluorescent dye rhodamine 6G (2 mg/ml; Molecular Probes) was given intravenously. Rhodamine 6G stains nuclei and mitochondria in living cells, thereby permitting visualization of interacting and freely flowing leukocytes in LN HEVs by fluorescent stroboscopic epi-illumination through a 20x Zeiss objective. Video scenes were recorded through a low-lag SIT camera (Dage MTI) and stored on Hi 8 videotape for off-line analysis of rolling fractions, rolling velocities, and microvascular hemodynamics as described [U. H. von Andrian et al., Am. J. Physiol. 263, H1034 (1992)]. After a 3- to 5-min control recording of HEVs, some animals were treated with mAb Mel-14 [100 19 per mouse, intravenously (iv)], and leukocyte behavior in the same vascular bed was recorded 15 min later. (11.) R. A. Warnock, E. C. Butcher, U. H. von Andrian, unpublished data.

(12.) Human platelets were purified from the blood of healthy donors by standard procedures. Aliquots of platelets were stimulated with human thrombin (Sigma; 0.5 U/ml for 5 min) or TRAP (Bachem; 25 [mu]m for 5 min) in the presence of 2 mM Arg-GI-Asp-Ser (RODS) (Peninsula Labs) to minimize aggregation. Excess thrombin was neutralized with hirudin (Sigma; 0.5 [mu]g/ml, 5 min, 37[degrees]C) before injection into the animal. Activation status of platelets was confirmed by flow cytometry of P-selectin expression. Aliquots of activated platelets were incubated with mAb WAPS 12.2 (20 [mu]g/ml) [M. A. Jutila et al., J. Immunol. 153, 3917 (1994)] or control mAb PECAM-1 [F. Liau et al., J. Exp. Med. 182, 1337 (1995)]. In experiments requiring direct visualization of circulating platelets, cells were fluorescently labeled with 2',7'-bis-(2-carboxyethyl)-5 (and-6) carboxyfluorescein (BCECF; Molecular Probes) as described [T. G. Diacovo, A. R. de Fougerolles, D. F. Bainton, T. A. Springer, J. Clin. Invest. 94, 1243 (1994)]. Fluorescent platelets were injected through the femoral artery catheter into the arterial bloodstream supplying the mode. In some experiments (n = 3), mAb MECA-79 (100 [mu]g per mouse, iv) was injected after assessment of rolling in untreated HEVs. After allowing mAb binding to PNAd for 10 min, freshly activated platelets or transfectants were again injected to assess the effects of mAb treatment.

(13.) T. G. Diacovo and U. H. von Andrian, data not shown.


A cDNA encoding full length P-selectin was isolated by polymerase chain reaction from the human megakaryocyte cell line HEL 92.17 "American Type Culture Collection). Sequence fidelity was verified by restriction analysis and sequencing (14). The P-selectin cDNA was subcloned into pMRB101 to stably transfect murine L1-2 pre B cells as described (4, 30). High P-selectin-expressing subclones were grown in RPMI 1640 containing 10% fetal calf serum and standard supplements. For in vivo experiments, transfectants were labeled with BCECF, resuspended in RPMI (1 x 107 per milliliter), and injected into mice as described (12).


We thank B. Fors, E. Finger, and G. Cheng for technical assistance; E. Butcher, P. Newman, D. Wagner, G. Gaudernack, and R. McEver for contributing reagents; and K. Gauvreau for aiding in statistical analysis. Supported by National Institutes of Health grants HL48675 and HL54936.

14 February 1996; accepted 7 June 1996 T. G. Diacovo, Center for Blood Research and Department of Cardiology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA, and Division of Newborn Medicine, Department of Pediatrics, Tufts University School of Medicine, Boston, MA 02111, USA.

K. D. Puri, T. A. Springer, U. H. von Andrian, Center for Blood Research and Department of Pathology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA.